141 related articles for article (PubMed ID: 29656586)
1. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
Italiano A; Touati N; Litière S; Collin F; Pourquier P; Gronchi A
Cancer Med; 2018 May; 7(5):1575-1577. PubMed ID: 29656586
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.
Laroche-Clary A; Chaire V; Le Morvan V; Neuville A; Bertucci F; Salas S; Sanfilippo R; Pourquier P; Italiano A
Br J Cancer; 2015 Feb; 112(4):688-92. PubMed ID: 25602962
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response.
Souid S; Aissaoui D; Srairi-Abid N; Essafi-Benkhadir K
Curr Drug Targets; 2020; 21(10):996-1007. PubMed ID: 31994460
[TBL] [Abstract][Full Text] [Related]
6. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Moura DS; Peña-Chilet M; Cordero Varela JA; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ramos R; Ortega-Medina L; Martin-Davila F; Castilla-Ramirez C; Hernandez-Leon CN; Romagosa C; Vaz Salgado MA; Lavernia J; Bagué S; Mayodormo-Aranda E; Vicioso L; Hernández Barceló JE; Rubio-Casadevall J; de Juan A; Fiaño-Valverde MC; Hindi N; Lopez-Alvarez M; Lacerenza S; Dopazo J; Gutierrez A; Alvarez R; Valverde C; Martinez-Trufero J; Martín-Broto J
Mol Oncol; 2021 Dec; 15(12):3691-3705. PubMed ID: 33983674
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
[TBL] [Abstract][Full Text] [Related]
9. Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial.
Penel N; Decoupigny E; Tresch-Bruneel E; Le Cesne A; Taieb S; Isambert N
Am J Clin Oncol; 2019 Sep; 42(9):737. PubMed ID: 31449140
[No Abstract] [Full Text] [Related]
10. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
[TBL] [Abstract][Full Text] [Related]
11. Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials.
Endo M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Goda K; Kawai A
Cancer Med; 2020 Jun; 9(11):3656-3667. PubMed ID: 32220056
[TBL] [Abstract][Full Text] [Related]
12. Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines.
Iwasaki J; Komori T; Nakagawa F; Nagase H; Uchida J; Matsuo K; Uto Y
Anticancer Res; 2019 Jul; 39(7):3553-3563. PubMed ID: 31262879
[TBL] [Abstract][Full Text] [Related]
13. Making the Best of Available Options for Optimal Sarcoma Treatment.
Le Cesne A
Oncology; 2018; 95 Suppl 1():11-20. PubMed ID: 30554197
[TBL] [Abstract][Full Text] [Related]
14. CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin.
Esser M; Kloth C; Thaiss WM; Reinert CP; Fritz J; Kopp HG; Horger M
Eur J Radiol; 2018 Oct; 107():175-182. PubMed ID: 30292263
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
16. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Zhou DD; King D; Thomson K; Grimison P
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e526-e528. PubMed ID: 35297193
[No Abstract] [Full Text] [Related]
18. Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?
Assi T; Cesne AL
Immunotherapy; 2023 Jan; 15(1):5-8. PubMed ID: 36628569
[No Abstract] [Full Text] [Related]
19. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
